Table 1.
Patient characteristics of the CT group.
| Characteristics | Total, n (%) | CT-BB, n (%) | CT-RP, n (%) | p Value a |
|---|---|---|---|---|
| Age | 0.828 | |||
| ≧65 | 25 (42.4) | 11 (44.0) | 14 (41.2) | |
| <65 | 34 (57.6) | 14 (56.0) | 20 (58.8) | |
| Gender, n (%) | 0.687 | |||
| Male | 23 (39.0) | 9 (36.0) | 14 (41.2) | |
| Female | 36 (61.0) | 16 (64.0) | 20 (58.8) | |
| Smoking status, n (%) | 0.861 | |||
| Never-smokers | 37 (62.7) | 16 (64.0) | 21 (61.8) | |
| Former or current smokers | 22 (37.3) | 9 (36.0) | 13 (38.2) | |
| ECOG PS, n (%) | 0.215 | |||
| 0–1 | 51 (86.4) | 20 (80.0) | 31 (91.2) | |
| 2–4 | 8 (13.6) | 5 (20.0) | 3 (8.8) | |
| Stage, n (%) | 0.471 | |||
| Stage 4A | 22 (37.3) | 8 (32.0) | 14 (41.2) | |
| Stage 4B | 37 (62.7) | 17 (68.0) | 20 (58.8) | |
| Regimen | 0.296 | |||
| Cisplatin | 42 (71.2) | 16 (64.0) | 26 (76.5) | |
| Carboplatin | 17 (28.8) | 9 (36.0) | 8 (23.5) | |
| Driver mutation (EGFR/ALK/ROS1) | 0.708 | |||
| Yes | 30 (50.8) | 12 (48.0) | 18 (52.9) | |
| No | 29 (49.2) | 13 (52.0) | 16 (47.1) | |
| Objective response rate | 32.8% | 42.4% | 0.579 | |
| Disease control rate | 78.3% | 75.8% | 0.667 |
a
By Fisher’s exact test.
ALK, anaplastic lymphoma kinase; BB, bevacizumab biosimilar; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ROS1, ROS proto-oncogene 1; RP, reference product.